Metraipolis › archive › dc_27f3e39729af
Disproportionality analysis of safety signals for milnacipran and levomilnacipran: a pharmacovigilance study using the FDA adverse event reporting system — Europe PMC PMID:41458966
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41458966
- DOI
- 10.3389/fphar.2025.1719881
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T17:45:58.411Z
- SHA-256 of the archived text
25db1de00151f91c963312d173594a681a77b0e912af62203a90a6a193e65dfd- Stable URL of this page
https://metraipolis.com/documento/dc_27f3e39729af
How to cite
Disproportionality analysis of safety signals for milnacipran and levomilnacipran: a pharmacovigilance study using the FDA adverse event reporting system — Europe PMC PMID:41458966 — Europe PMC (en), https://europepmc.org/article/MED/41458966 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_27f3e39729af (Metraipolis archive dc_27f3e39729af, sha256 25db1de00151f91c963312d173594a681a77b0e912af62203a90a6a193e65dfd)
BibTeX
@misc{dc27f3e39729af,
title = {Disproportionality analysis of safety signals for milnacipran and levomilnacipran: a pharmacovigilance study using the FDA adverse event reporting system — Europe PMC PMID:41458966},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41458966},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_27f3e39729af; sha256 25db1de00151f91c963312d173594a681a77b0e912af62203a90a6a193e65dfd},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41458966. Agents can read the archived copy with the MCP tool read_document.